Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Jr Howard J.F., K. Utsugisawa, M. Benatar, H. Murai, R.J. Barohn, I. Illa, S. Jacob, J. Vissing, T.M. Burns, J.T. Kissel, S. Muppidi, R.J. Nowak, F. O'Brien, J.-J. Wang, R. Mantegazza, C.G. Mazia, M. Wilken, C. Ortea, J. Saba, M. RugieroM. Bettini, G. Vidal, A.D. Garcia, P. Lamont, W.-K. Leong, H. Boterhoven, B. Fyfe, L. Roberts, M. Jasinarachchi, N. Willlems, J. Wanschitz, W. Löscher, J. De Bleecker, G. Van den Abeele, K. de Koning, K. De Mey, C. Miranda, S. Bonanno, C. Antozzi, L. Maggi, A. Campanella, C. Angelini, P. Cudia, V. Pegoraro, F. Bevilacqua, R. Iorio, M. Gabriele, S. Messina, A. Amato, S. Scala

Research output: Contribution to journal › Article

Original languageItalian
Pages (from-to)976-986
Number of pages11
JournalThe Lancet Neurology
Volume16
Issue number12
DOIs
Publication statusPublished - 2017

Cite this

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. / Howard J.F., Jr; Utsugisawa, K.; Benatar, M.; Murai, H.; Barohn, R.J.; Illa, I.; Jacob, S.; Vissing, J.; Burns, T.M.; Kissel, J.T.; Muppidi, S.; Nowak, R.J.; O'Brien, F.; Wang, J.-J.; Mantegazza, R.; Mazia, C.G.; Wilken, M.; Ortea, C.; Saba, J.; Rugiero, M.; Bettini, M.; Vidal, G.; Garcia, A.D.; Lamont, P.; Leong, W.-K.; Boterhoven, H.; Fyfe, B.; Roberts, L.; Jasinarachchi, M.; Willlems, N.; Wanschitz, J.; Löscher, W.; De Bleecker, J.; Van den Abeele, G.; de Koning, K.; De Mey, K.; Miranda, C.; Bonanno, S.; Antozzi, C.; Maggi, L.; Campanella, A.; Angelini, C.; Cudia, P.; Pegoraro, V.; Bevilacqua, F.; Iorio, R.; Gabriele, M.; Messina, S.; Amato, A.; Scala, S.

In: The Lancet Neurology, Vol. 16, No. 12, 2017, p. 976-986.

Research output: Contribution to journal › Article

Howard J.F., J, Utsugisawa, K, Benatar, M, Murai, H, Barohn, RJ, Illa, I, Jacob, S, Vissing, J, Burns, TM, Kissel, JT, Muppidi, S, Nowak, RJ, O'Brien, F, Wang, J-J, Mantegazza, R, Mazia, CG, Wilken, M, Ortea, C, Saba, J, Rugiero, M, Bettini, M, Vidal, G, Garcia, AD, Lamont, P, Leong, W-K, Boterhoven, H, Fyfe, B, Roberts, L, Jasinarachchi, M, Willlems, N, Wanschitz, J, Löscher, W, De Bleecker, J, Van den Abeele, G, de Koning, K, De Mey, K, Miranda, C, Bonanno, S, Antozzi, C, Maggi, L, Campanella, A, Angelini, C, Cudia, P, Pegoraro, V, Bevilacqua, F, Iorio, R, Gabriele, M, Messina, S, Amato, A & Scala, S 2017, 'Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study', The Lancet Neurology, vol. 16, no. 12, pp. 976-986. https://doi.org/10.1016/S1474-4422(17)30369-1
Howard J.F. J, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. The Lancet Neurology. 2017;16(12):976-986. https://doi.org/10.1016/S1474-4422(17)30369-1
Howard J.F., Jr ; Utsugisawa, K. ; Benatar, M. ; Murai, H. ; Barohn, R.J. ; Illa, I. ; Jacob, S. ; Vissing, J. ; Burns, T.M. ; Kissel, J.T. ; Muppidi, S. ; Nowak, R.J. ; O'Brien, F. ; Wang, J.-J. ; Mantegazza, R. ; Mazia, C.G. ; Wilken, M. ; Ortea, C. ; Saba, J. ; Rugiero, M. ; Bettini, M. ; Vidal, G. ; Garcia, A.D. ; Lamont, P. ; Leong, W.-K. ; Boterhoven, H. ; Fyfe, B. ; Roberts, L. ; Jasinarachchi, M. ; Willlems, N. ; Wanschitz, J. ; Löscher, W. ; De Bleecker, J. ; Van den Abeele, G. ; de Koning, K. ; De Mey, K. ; Miranda, C. ; Bonanno, S. ; Antozzi, C. ; Maggi, L. ; Campanella, A. ; Angelini, C. ; Cudia, P. ; Pegoraro, V. ; Bevilacqua, F. ; Iorio, R. ; Gabriele, M. ; Messina, S. ; Amato, A. ; Scala, S. / Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. In: The Lancet Neurology. 2017 ; Vol. 16, No. 12. pp. 976-986.
@article{fded4c2e156a463aa01118ca965daf14,
title = "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study",
author = "{Howard J.F.}, Jr and K. Utsugisawa and M. Benatar and H. Murai and R.J. Barohn and I. Illa and S. Jacob and J. Vissing and T.M. Burns and J.T. Kissel and S. Muppidi and R.J. Nowak and F. O'Brien and J.-J. Wang and R. Mantegazza and C.G. Mazia and M. Wilken and C. Ortea and J. Saba and M. Rugiero and M. Bettini and G. Vidal and A.D. Garcia and P. Lamont and W.-K. Leong and H. Boterhoven and B. Fyfe and L. Roberts and M. Jasinarachchi and N. Willlems and J. Wanschitz and W. L{\"o}scher and {De Bleecker}, J. and {Van den Abeele}, G. and {de Koning}, K. and {De Mey}, K. and C. Miranda and S. Bonanno and C. Antozzi and L. Maggi and A. Campanella and C. Angelini and P. Cudia and V. Pegoraro and F. Bevilacqua and R. Iorio and M. Gabriele and S. Messina and A. Amato and S. Scala",
note = "Cited By :4 Export Date: 7 March 2018",
year = "2017",
doi = "10.1016/S1474-4422(17)30369-1",
language = "Italian",
volume = "16",
pages = "976--986",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

AU - Howard J.F., Jr

AU - Utsugisawa, K.

AU - Benatar, M.

AU - Murai, H.

AU - Barohn, R.J.

AU - Illa, I.

AU - Jacob, S.

AU - Vissing, J.

AU - Burns, T.M.

AU - Kissel, J.T.

AU - Muppidi, S.

AU - Nowak, R.J.

AU - O'Brien, F.

AU - Wang, J.-J.

AU - Mantegazza, R.

AU - Mazia, C.G.

AU - Wilken, M.

AU - Ortea, C.

AU - Saba, J.

AU - Rugiero, M.

AU - Bettini, M.

AU - Vidal, G.

AU - Garcia, A.D.

AU - Lamont, P.

AU - Leong, W.-K.

AU - Boterhoven, H.

AU - Fyfe, B.

AU - Roberts, L.

AU - Jasinarachchi, M.

AU - Willlems, N.

AU - Wanschitz, J.

AU - Löscher, W.

AU - De Bleecker, J.

AU - Van den Abeele, G.

AU - de Koning, K.

AU - De Mey, K.

AU - Miranda, C.

AU - Bonanno, S.

AU - Antozzi, C.

AU - Maggi, L.

AU - Campanella, A.

AU - Angelini, C.

AU - Cudia, P.

AU - Pegoraro, V.

AU - Bevilacqua, F.

AU - Iorio, R.

AU - Gabriele, M.

AU - Messina, S.

AU - Amato, A.

AU - Scala, S.

N1 - Cited By :4 Export Date: 7 March 2018

PY - 2017

Y1 - 2017

U2 - 10.1016/S1474-4422(17)30369-1

DO - 10.1016/S1474-4422(17)30369-1

M3 - Articolo

VL - 16

SP - 976

EP - 986

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 12

ER -

Access to Document

Related content

Projects

S.CAMILLO - NEUROFARMACOLOGIA IN NEURORIABILITAZIONE

Project: Other project